Treatment of advanced Parkinson’s disease

References

• Parkinson J. An essay on the shaking palsy. Medical Classics10, 964–967 (1817).
   Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N. Engl. J Med.276(7), 374–379 (1967).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch. Neurol.62(3), 351–352 (2005).
   PubMedGoogle Scholar
• Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson’s disease. Arch. Neurol.36(5), 308–310 (1979).
   PubMedGoogle Scholar
• Currie LJ, Harrison MB, Trugman JM, Bennett JP Jr, Wooten GF. Early morning dystonia in Parkinson’s disease. Neurology51(1), 283–285 (1998).
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five-year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol. Neurosurg. Psychiatry57(8), 903–910 (1994).
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord.20(2), 190–199 (2005).
   PubMed Web of Science ®Google Scholar
• Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov. Disord.19(1), 22–28 (2004).
   PubMed Web of Science ®Google Scholar
• Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch. Neurol.63(2), 205–209 (2006).
   PubMedGoogle Scholar
• Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J. Neurol. Neurosurg. Psychiatry76(9), 1188–1193 (2005).
   PubMed Web of Science ®Google Scholar
• Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y. The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov. Disord.14(Suppl. 1), 13–18 (1999).
   PubMedGoogle Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord.20(Suppl. 11), S11–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Fuente-Fernandez R, Sossi V, Huang Z et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain127(Pt 12), 2747–2754 (2004).
   PubMedGoogle Scholar
• Lhermitte F, Agid Y, Feuerstein C et al. Abnormal movements caused by L-DOPA in patients with Parkinson’s disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA. Rev. Neurol.133(8–9), 445–454 (1977).
   PubMedGoogle Scholar
• Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa Arch. Neurol.35(5), 261–263 (1978).
   PubMedGoogle Scholar
• Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov. Disord.20(Suppl. 11), S3–S10 (2005).
   PubMedGoogle Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16(3), 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann. Neurol.39(1), 37–45 (1996).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord.19(9), 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res.547(1), 142–151 (1991).
   PubMed Web of Science ®Google Scholar
• Gerfen CR. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson’s disease. Neuroscientist9(6), 455–462 (2003).
   PubMed Web of Science ®Google Scholar
• Morissette M, Goulet M, Soghomonian JJ et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res. Mol. Brain Res.49(1–2), 55–62 (1997).
   PubMedGoogle Scholar
• Goulet M, Morissette M, Calon F et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience79(2), 497–507 (1997).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N. Engl. J Med.310(8), 483–488 (1984).
   PubMed Web of Science ®Google Scholar
• Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov. Disord.20(11), 1397–1404 (2005).
   PubMed Web of Science ®Google Scholar
• Koller WC, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology44(7 Suppl. 6), S23–S28 (1994).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Busenbark K, Huber SJ et al. Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology43(4), 677–681 (1993).
   PubMedGoogle Scholar
• Pahwa R, Lyons K, McGuire D et al. Early morning akinesia in Parkinson’s disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Neurology46(4), 1059–1062 (1996).
   PubMedGoogle Scholar
• Nilsson D, Hansson LE, Johansson K et al. Long-term intraduodenal infusion of a water based levodopa–carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol. Scand.97(3), 175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease-long-term experience. Acta Neurol. Scand.104(6), 343–348 (2001).
   PubMed Web of Science ®Google Scholar
• Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson’s disease. Clin. Neuropharmacol.24(3), 150–157 (2001).
   PubMed Web of Science ®Google Scholar
• Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin. Neuropharmacol.19(4), 283–296 (1996).
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs59(6), 1233–1250 (2000).
   PubMed Web of Science ®Google Scholar
• Ahtila S, Kaakkola S, Gordin A et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol.18(1), 46–57 (1995).
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ, Korpela K et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry68(5), 589–594 (2000).
   PubMed Web of Science ®Google Scholar
• Najib J. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson’s disease. Clin. Ther.23(6), 802–832 (2001).
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Agid Y, Eggert K et al. Treatment of end-of-dose wearing-off in Parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur. Neurol.53(4), 197–202 (2005).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand.105(4), 245–255 (2002).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet365(9463), 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology51(5), 1309–1314 (1998).
   PubMed Web of Science ®Google Scholar
• Roberts JW, Cora-Locatelli G, Bravi D et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology43(12), 2685–2688 (1993).
   PubMed Web of Science ®Google Scholar
• Kurth MC, Adler CH, Hilaire MS et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology48(1), 81–87 (1997).
   PubMed Web of Science ®Google Scholar
• Adler CH, Singer C, O’Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol.55(8), 1089–1095 (1998).
   PubMedGoogle Scholar
• Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov. Disord.12(6), 928–934 (1997).
   PubMed Web of Science ®Google Scholar
• Koller W, Lees A, Doder M, Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov. Disord.16(5), 858–866 (2001).
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet352(9132), 958 (1998).
   PubMed Web of Science ®Google Scholar
• Watkins P. COMT inhibitors and liver toxicity. Neurology55(11 Suppl. 4), S51–S52 (2000).
   Google Scholar
• Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology62(1 Suppl. 1), S39–S46 (2004).
   PubMed Web of Science ®Google Scholar
• Golbe LI, Lieberman AN, Muenter MD et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin. Neuropharmacol.11(1), 45–55 (1988).
   PubMed Web of Science ®Google Scholar
• Hubble JP. Novel drugs for Parkinson’s disease. Med. Clin. North Am.83(2), 525–536 (1999).
   PubMedGoogle Scholar
• Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol.50(4), 375–382 (1998).
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord.19(4), 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett.355(3), 169–172 (2004).
   PubMed Web of Science ®Google Scholar
• Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural. Transm.52(Suppl. 5) 2287–3000 (1998).
   Google Scholar
• Hauser RA, Lew MF, Hurtig H, Ondo W, Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of parkinson’s disease: Analyses of the TEMPO ITT cohort Parkinsonism. Relat. Disord.11(Suppl. 2), 129 (2005).
   Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol.59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol.61(4), 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Eberly S, Oakes D. Reexamination of the TEMPO study. Arch. Neurol.621320–1321 (2005).
   PubMedGoogle Scholar
• Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov. Disord.19(8), 916–923 (2004).
   PubMed Web of Science ®Google Scholar
• Lew MF, Hauser RA, Hurtig H, Ondo W, Wojcieszek J. Long-term efficacy of rasagiline in Parkinson’s disease patients Parkinsonism. Relat. Disord.11(Suppl. 2), 129 (2005).
   Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline is effective and well tolerated in the treatment of moderate to advanced Parkinson’s disease (PD) patients receiving concomitant dopamine agonist therapy Parkinsonism. Relat. Disord.11(Suppl. 2), 129 (2005).
   Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol.62(2), 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Biglan KM, Schwid S, Eberly S et al. Rasagiline improves quality of life in patients with early Parkinson’s disease. Mov. Disord.21(5), 616–623 (2006).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists Can. J. Neurol. Sci.26(Suppl. 2) S27–S33 (1999).
   Google Scholar
• Maj J, Rogoi Z, Margas W, Kata M, Dziedzicka-Wasylewska M. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J. Neural. Transm.107(12), 1369–1379 (2000).
   PubMed Web of Science ®Google Scholar
• Piercey MF, Walker EL, Feldpausch DL, Camacho-Ochoa M. High-affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci. Lett.219(2), 138–140 (1996).
   PubMed Web of Science ®Google Scholar
• Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol.37(6), 520–525 (1997).
   PubMed Web of Science ®Google Scholar
• Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov. Disord.20(5), 602–610 (2005).
   PubMed Web of Science ®Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology49(4), 1060–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4. 4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol.127(7), 1696–1702 (1999).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology51(4), 1057–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Rascol O, Lees AJ, Senard JM et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin. Neuropharmacol.19(3), 234–245 (1996).
   PubMed Web of Science ®Google Scholar
• Blin O. The pharmacokinetics of pergolide in Parkinson’s disease. Curr. Opin. Neurol.16(Suppl. 1), S9–12 (2003).
   Google Scholar
• Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson’s disease. Curr. Opin. Neurol.16(Suppl. 1), S3–S7 (2003).
   PubMed Web of Science ®Google Scholar
• Thalamas C, Rajman I, Kulisevsky J et al. Pergolide: multiple-dose pharmacokinetics in patients with mild-to-moderate Parkinson disease. Clin. Neuropharmacol.28(3), 120–125 (2005).
   PubMedGoogle Scholar
• Jankovic J. Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy. Neurology33(4), 505–507 (1983).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Long-term study of pergolide in Parkinson’s disease. Neurology35(3), 296–299 (1985).
   PubMedGoogle Scholar
• Jankovic J. Long-term use of dopamine agonists in Parkinson’s disease. Clin. Neuropharmacol.8(2), 131–140 (1985).
   PubMedGoogle Scholar
• Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson’s disease. Adv. Neurol.45, 551–554 (1987).
   PubMedGoogle Scholar
• Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov. Disord.9(1), 40–47 (1994).
   PubMed Web of Science ®Google Scholar
• Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology61(6), 859–861 (2003).
   PubMed Web of Science ®Google Scholar
• Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch. Neurol.62(8), 1290–1295 (2005).
   PubMedGoogle Scholar
• Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet363(9416), 1179–1183 (2004).
   PubMed Web of Science ®Google Scholar
• Horvath J, Fross RD, Kleiner-Fisman G et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord.19(6), 656–662 (2004).
   PubMed Web of Science ®Google Scholar
• Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin. Pharmacokinet.42(7), 633–645 (2003).
   PubMed Web of Science ®Google Scholar
• Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs55(Suppl. 1), 17–22 (1998).
   PubMedGoogle Scholar
• Rabey JM, Oberman Z, Scharf M et al. The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson’s disease. Clin. Neuropharmacol.12(5), 440–447 (1989).
   PubMedGoogle Scholar
• Mizuno Y, Yanagisawa N, Kuno S et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov. Disord.18(10), 1149–1156 (2003).
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Bedard PJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther.259(1), 409–413 (1991).
   PubMedGoogle Scholar
• Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson’s disease: a wake-up call. Mov. Disord.15(4), 601–603 (2000).
   PubMedGoogle Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52(9), 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA287(4), 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology61(3), 422–423 (2003).
   PubMed Web of Science ®Google Scholar
• Kurlan R. Disabling repetitive behaviors in Parkinson’s disease. Mov. Disord.19(4), 433–437 (2004).
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol.62(9), 1377–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs. Arch. Neurol.63(2), 298–299 (2006).
   PubMedGoogle Scholar
• Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch. Neurol.57(5), 729–732 (2000).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin. Neuropharmacol.10(6), 522–526 (1987).
   PubMedGoogle Scholar
• Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov. Disord.15(5), 873–878 (2000).
   PubMed Web of Science ®Google Scholar
• Parkes JD, Zilkha KJ, Marsden P, Baxter RC, Knill-Jones RP. Amantadine dosage in treatment of Parkinson’s disease. Lancet1(7657), 1130–1133 (1970).
   PubMed Web of Science ®Google Scholar
• Singer C, Papapetropoulos S, Gonzalez MA, Roberts EL, Lieberman A. Rimantadine in Parkinson’s disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov. Disord.20(7), 873–877 (2005).
   PubMedGoogle Scholar
• Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology60(1), 69–73 (2003).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Palfi S, Chen EY et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol.46(3), 419–424 (1999).
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med.9(5), 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK et al. Randomized-controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59(3), 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Colosimo C, Merello M, Albanese A. clinical usefulness of apomorphine in movement disorders. Clin. Neuropharmacol.17(3), 243–259 (1994).
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry53(2), 96–101 (1990).
   PubMed Web of Science ®Google Scholar
• Stacy M. Apomorphine: North American clinical experience. Neurology62(6 Suppl. 4), S18–S21 (2004).
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch. Neurol.58(9), 1385–1392 (2001).
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. Intranasal apomorphine rescue therapy for parkinsonian “off” periods. Clin. Neuropharmacol.19(3), 193–201 (1996).
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson’s disease. Mov. Disord.13(5), 782–787 (1998).
   PubMed Web of Science ®Google Scholar
• Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson’s disease. Mov. Disord.14(4), 664–668 (1999).
   PubMed Web of Science ®Google Scholar
• Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson’s disease. Clin. Neuropharmacol.22(1), 1–4 (1999).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, De Pandis MF et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol. Sci.22(1), 93–94 (2001).
   PubMed Web of Science ®Google Scholar
• Priano L, Albani G, Calderoni S et al. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson’s disease. Neurol. Sci.23(Suppl. 2), S99–S100 (2002).
   Google Scholar
• Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology46(4), 1051–1054 (1996).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur. J. Clin. Pharmacol.54(4), 303–308 (1998).
   PubMed Web of Science ®Google Scholar
• Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson’s patients with severe fluctuations: a pilot study. Neurology43(5), 1036–1039 (1993).
   PubMedGoogle Scholar
• Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov. Disord.9(4), 463–465 (1994).
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Goetz CG, Niederman F et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology47(6), 1493–1495 (1996).
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson’s disease. Ann. Neurol.39(3), 400–404 (1996).
   PubMed Web of Science ®Google Scholar
• Blindauer K, Shoulson I, Oakes D et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch. Neurol.63(2), 210–216 (2006).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst. Rev. (3), CD002259 (2000).
   Google Scholar
• Metman LV, Del Dotto P, LePoole K et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol.56(11), 1383–1386 (1999).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Rajput A, Lang AE et al. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov. Disord.13(5), 851 (1998).
   PubMed Web of Science ®Google Scholar
• Silva-Junior FP, Braga-Neto P, Sueli MF, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat. Disord.11(7), 449–452 (2005).
   PubMedGoogle Scholar
• Thomas A, Iacono D, Luciano AL et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry75(1), 141–143 (2004).
   PubMed Web of Science ®Google Scholar
• Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson’s disease. Lancet353(9166), 1764–1765 (1999).
   PubMed Web of Science ®Google Scholar
• Lokk J. Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure. Lakartidningen.101(23), 2003–2006 (2004).
   PubMedGoogle Scholar
• Verhagen ML, Del Dotto P, Natte R, van den MP, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology51(1), 203–206 (1998).
   PubMedGoogle Scholar
• Durif F, Debilly B, Galitzky M et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology62(3), 381–388 (2004).
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol.27(4), 153–156 (2004).
   PubMed Web of Science ®Google Scholar
• Sa DS, Lang AE. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology57(4), 747 (2001).
   PubMedGoogle Scholar
• Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson’s disease. Neurology46(6), 1548–1551 (1996).
   PubMedGoogle Scholar
• Tousi B, Subramanian T. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson’s disease. Parkinsonism Relat. Disord.11(5), 333–334 (2005).
   PubMedGoogle Scholar
• Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Mov. Disord.20(9), 1205–1209 (2005).
   PubMed Web of Science ®Google Scholar
• Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease. Mov. Disord.20(4), 403–409 (2005).
   PubMedGoogle Scholar
• Durif F, Deffond D, Dordain G, Tournilhac M. Apomorphine and diphasic dyskinesia. Clin. Neuropharmacol.17(1), 99–102 (1994).
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Albani G, Martignoni E et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov. Disord.10(3), 333–336 (1995).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson’s disease: clinical and pharmacological features. Ann. Neurol.23(1), 73–78 (1988).
   PubMed Web of Science ®Google Scholar
• Pogarell O, Gasser T, van Hilten JJ et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo- controlled multicentre study. J. Neurol. Neurosurg. Psychiatry72(6), 713–720 (2002).
   PubMed Web of Science ®Google Scholar
• Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov. Disord.18(11), 1324–1331 (2003).
   PubMedGoogle Scholar
• Navan P, Findley LJ, Undy MB, Pearce RK, Bain PG. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur. J. Neurol.12(1), 1–8 (2005).
   PubMedGoogle Scholar
• Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging16(4), 273–278 (2000).
   PubMed Web of Science ®Google Scholar
• Koller WC, Herbster G. Adjuvant therapy of parkinsonian tremor. Arch. Neurol.44(9), 921–923 (1987).
   PubMedGoogle Scholar
• Crosby NJ, Deane KH, Clarke CE. β-blocker therapy for tremor in Parkinson’s disease. Cochrane Database Syst. Rev. (1), CD003361 (2003).
   Google Scholar
• Nakanishi I, Kohmoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei55(8), 685–689 (2003).
   PubMedGoogle Scholar
• Jansen EN. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol. Scand.89(4), 262–265 (1994).
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst. Rev. (2), CD003735 (2003).
   Google Scholar
• Giladi N, McDermott MP, Fahn S et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology56(12), 1712–1721 (2001).
   PubMed Web of Science ®Google Scholar
• Giladi N. Freezing of gait. Clinical overview. Adv. Neurol.87, 191–197 (2001).
   PubMedGoogle Scholar
• Giladi N, Treves TA, Simon ES et al. Freezing of gait in patients with advanced Parkinson’s disease. J. Neural. Transm.108(1), 53–61 (2001).
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S et al. Monoamine metabolism in the cerebrospinal fluid in Parkinson’s disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J. Neural. Transm. Park Dis. Dement. Sect.5(1), 17–26 (1993).
   PubMedGoogle Scholar
• Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural. Transm. Park Dis. Dement. Sect.5(1), 27–34 (1993).
   PubMedGoogle Scholar
• Tohgi H, Abe T, Takahashi S et al. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci. Lett.116(1–2), 194–197 (1990).
   PubMed Web of Science ®Google Scholar
• Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J. Neurol.248(7), 572–576 (2001).
   PubMedGoogle Scholar
• Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson’s disease. Med. Sci. Monit.10(7), CR282–CR284 (2004).
   PubMedGoogle Scholar
• Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology65(4), 626–628 (2005).
   PubMedGoogle Scholar
• Witjas T, Kaphan E, Azulay JP et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology59(3), 408–413 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60(3), 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord.20(10), 1255–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon KM, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology661–1 (2006).
   PubMedGoogle Scholar
• Suchowersky O, Reich S, Perlmutter J et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology66(7), 978–975 (2006).
   Google Scholar
• Aarsland D, Litvan I, Salmon D et al. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry74(9), 1215–1220 (2003).
   PubMed Web of Science ®Google Scholar
• Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord.18(5), 467–486 (2003).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology65(10), 1654–1656 (2005).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo-controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Burn DJ, Rowan EN et al. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int. J. Geriatr. Psychiatry20(10), 938–944 (2005).
   PubMed Web of Science ®Google Scholar
• Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain125(Pt 11), 2431–2445 (2002).
   PubMed Web of Science ®Google Scholar
• Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain125(Pt 2), 391–403 (2002).
   PubMed Web of Science ®Google Scholar
• Factor SA, Feustel PJ, Friedman JH et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology60(11), 1756–1761 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology43(11), 2227–2229 (1993).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology45(4), 669–671 (1995).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology51(3), 811–814 (1998).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology56(11 Suppl. 5), S1–S88 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.15(2), 201–211 (2000).
   PubMed Web of Science ®Google Scholar
• Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov. Disord.17(3), 445–454 (2002).
   PubMed Web of Science ®Google Scholar
• Burn DJ. Depression in Parkinson’s disease. Eur. J. Neurol.9(Suppl. 3), 44–54 (2002).
   PubMed Web of Science ®Google Scholar
• Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10(4), 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Chou KL, Hurtig HI, Jaggi JL et al. Electroconvulsive therapy for depression in a Parkinson’s disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat. Disord.11(6), 403–406 (2005).
   PubMed Web of Science ®Google Scholar
• Fall PA, Granerus AK. Maintenance ECT in Parkinson’s disease. J. Neural. Transm.106(7–8), 737–741 (1999).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology25(12), 1144–1148 (1975).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic nervous system dysfunction in Parkinson’s disease. Curr. Treat. Options Neurol.5(2), 149–160 (2003).
   PubMedGoogle Scholar
• Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson’s disease. Am. J. Gastroenterol.89(1), 15–25 (1994).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Odaka T, Uchiyama T et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry74(2), 268–272 (2003).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology57(3), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann. Neurol.33(5), 490–493 (1993).
   PubMed Web of Science ®Google Scholar
• Albanese A, Maria G, Bentivoglio AR et al. Severe constipation in Parkinson’s disease relieved by botulinum toxin. Mov. Disord.12(5), 764–766 (1997).
   PubMed Web of Science ®Google Scholar
• Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov. Disord.21(1), 115–116 (2006).
   PubMed Web of Science ®Google Scholar
• Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. N. Engl. J. Med.346(15), 1174–1175 (2002).
   PubMed Web of Science ®Google Scholar
• Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology54(1), 244–247 (2000).
   PubMedGoogle Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology62(1), 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin. Neurol. Neurosurg.106(2), 93–96 (2004).
   PubMed Web of Science ®Google Scholar
• Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J. Urol.164(5), 1640–1643 (2000).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov. Disord.15(2), 305–308 (2000).
   PubMed Web of Science ®Google Scholar
• Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry71(3), 371–374 (2001).
   PubMed Web of Science ®Google Scholar
• Pavone C, Curto F, Anello G et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J. Urol.172(6 Pt 1), 2347–2349 (2004).
   PubMed Web of Science ®Google Scholar
• Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson’s disease. Curr. Opin. Neurol.17(4), 393–398 (2004).
   PubMedGoogle Scholar
• Wright RA, Kaufmann HC, Perera R et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology51(1), 120–124 (1998).
   PubMed Web of Science ®Google Scholar
• Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA277(13), 1046–1051 (1997).
   PubMed Web of Science ®Google Scholar
• Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch. Neurol.32(1), 50–51 (1975).
   PubMed Web of Science ®Google Scholar
• Abate G, Polimeni RM, Cuccurullo F, Puddu P, Lenzi S. Effects of indomethacin on postural hypotension in parkinsonism. Br. Med J.2(6203), 1466–1468 (1979).
   PubMed Web of Science ®Google Scholar
• Swinn L, Schrag A, Viswanathan R et al. Sweating dysfunction in Parkinson’s disease. Mov. Disord.18(12), 1459–1463 (2003).
   PubMed Web of Science ®Google Scholar
• Partinen M. Sleep disorder related to Parkinson’s disease. J. Neurol.244(4 Suppl. 1), S3–S6 (1997).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin. Neuropharmacol.11(6), 512–519 (1988).
   PubMed Web of Science ®Google Scholar
• Askenasy JJ, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J. Neurol. Neurosurg. Psychiatry53(9), 749–753 (1990).
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16(4), 622–630 (2001).
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med.4(4), 281–284 (2003).
   PubMed Web of Science ®Google Scholar
• Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology61(10), 1418–1420 (2003).
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov. Disord.14(6), 922–927 (1999).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Dat VK, Khan H et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology57(8), 1392–1396 (2001).
   PubMed Web of Science ®Google Scholar
• Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson’s disease with modafinil. J. Neurol.248(7), 632–634 (2001).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo- controlled parallel trial. J. Neurol. Neurosurg. Psychiatry76(12), 1636–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Paus S, Brecht HM, Koster J et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov. Disord.18(6), 659–667 (2003).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Wahba MN, Zesiewicz TA, McDowell AW. Modafinil treatment of pramipexole-associated somnolence. Mov. Disord.15(6), 1269–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Allen RP, Kushida CA, Atkinson MJ. Factor analysis of the International Restless Legs Syndrome Study Group’s scale for restless legs severity. Sleep Med.4(2), 133–135 (2003).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch. Neurol.59(3), 421–424 (2002).
   PubMed Web of Science ®Google Scholar
• Lang AE, Johnson K. Akathisia in idiopathic Parkinson’s disease. Neurology37(3), 477–481 (1987).
   PubMed Web of Science ®Google Scholar
• Comella CL, Goetz CG. Akathisia in Parkinson’s disease. Mov. Disord.9(5), 545–549 (1994).
   PubMedGoogle Scholar
• Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin. Neuropharmacol.29, 148–153 (2006).
   PubMed Web of Science ®Google Scholar
• Evans AH, Pavese N, Lawrence AD et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol.59, 852–858 (2006).
   PubMed Web of Science ®Google Scholar